Uncovering the pathology of a rare pediatric leukemia

A team of scientists has demonstrated the mechanism by which ETO2-GLIS2, a gene fusion, promotes the development of an aggressive form of pediatric leukemia. The findings, published in Cancer Cell, also reveal an opportunity for the development of therapeutics.

The study was co-authored by John Crispino, PhD, the Robert I. Lurie, MD, and Lora S. Lurie Professor of Medicine in the Division of Hematology and Oncology.

Acute megakaryoblastic (AMKL), a rare type of blood cancer predominantly found in children, has two major pediatric subgroups: AMKL in patients with Down syndrome and those without. While the disease in those with Down syndrome (DS) is relatively well-defined and carries a good prognosis, non-DS AMKL is much less well-understood.

Recently, scientists discovered that a gene fusion called ETO2-GLIS2—produced by an inversion on chromosome 16—is present in 20 to 30 percent of cases of non-DS AMKL, and is associated with a very poor patient prognosis. But up until now, it was unclear exactly how this blocks normal cell differentiation, a hallmark of leukemia.

In the current study, the scientists illustrated how ETO2-GLIS2 induces an irregular transcription network that underlies AMKL. They further demonstrated that expression of a peptide that inhibits ETO2-GLIS2 oligomerization could release the differentiation block—insights which could inform the development of novel therapeutics.

"Acute megakaryoblastic leukemia is a devastating that requires new targeted and efficacious therapies," Crispino said. "The discovery of the mechanism by which ETO2-GLIS2 fusion promotes leukemia provides important new insights into ways to target these malignant cells."

Explore further

Research leads to new treatment recommendations for a high-risk pediatric leukemia

More information: Cécile Thirant et al. ETO2-GLIS2 Hijacks Transcriptional Complexes to Drive Cellular Identity and Self-Renewal in Pediatric Acute Megakaryoblastic Leukemia, Cancer Cell (2017). DOI: 10.1016/j.ccell.2017.02.006
Journal information: Cancer Cell

Citation: Uncovering the pathology of a rare pediatric leukemia (2017, May 9) retrieved 22 October 2020 from https://medicalxpress.com/news/2017-05-uncovering-pathology-rare-pediatric-leukemia.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments